Oxford BioMedica Plc (OXB):企業の財務・戦略的SWOT分析

◆英語タイトル:Oxford BioMedica Plc (OXB) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH7057FSA
◆発行会社(調査会社):GlobalData
◆発行日:2020年12月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Oxford BioMedica Plc (OXB) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Oxford BioMedica plc (Oxford Biomedica) is a biopharmaceutical company involved in the development and commercialization of gene-based medicines. It has LentiVector, a sector leading lentiviral vector delivery platform. Based on this platform the company has developed a portfolio of gene and cell therapy product candidates in ophthalmology, oncology, central nervous system (CNS) and other therapy areas. It has partnership and license agreement with other companies to develop potential gene and cell therapy products. The company has presence in different locations in Oxfordshire, the UK. Oxford BioMedica is headquartered in Oxford, the UK.

Oxford BioMedica Plc Key Recent Developments

Nov 23,2020: Oxford Biomedica appoints Dr. Sam Rasty as Non-Executive Director
Oct 06,2020: Oxford Biomedica receives MHRA approval for fourth manufacturing suite in Oxbox
Sep 17,2020: Oxford Biomedica : Interim results for the six months ended 30 June2020
Aug 03,2020: Oxford Biomedica signs Development, Manufacture & License Agreement with Beam Therapeutics for LentiVector Platform for next generation CAR-T therapeutics
Jun 01,2020: Oxford Biomedica appoints Dr. Roch Doliveux as non-executive chairman

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Oxford BioMedica Plc – Key Facts
Oxford BioMedica Plc – Key Employees
Oxford BioMedica Plc – Key Employee Biographies
Oxford BioMedica Plc – Major Products and Services
Oxford BioMedica Plc – History
Oxford BioMedica Plc – Company Statement
Oxford BioMedica Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Oxford BioMedica Plc – Business Description
Other Break-up: Bioprocessing/Commercial Development
Performance
Other Break-up: Licence Fees & Incentives
Performance
Other Break-up: Platform
Overview
Performance
Other Break-up: Product
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Rest of world
Performance
Oxford BioMedica Plc – Corporate Strategy
Oxford BioMedica Plc – SWOT Analysis
SWOT Analysis – Overview
Oxford BioMedica Plc – Strengths
Oxford BioMedica Plc – Weaknesses
Oxford BioMedica Plc – Opportunities
Oxford BioMedica Plc – Threats
Oxford BioMedica Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Oxford BioMedica Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 23, 2020: Oxford Biomedica appoints Dr. Sam Rasty as Non-Executive Director
Oct 06, 2020: Oxford Biomedica receives MHRA approval for fourth manufacturing suite in Oxbox
Sep 17, 2020: Oxford Biomedica : Interim results for the six months ended 30 June2020
Aug 03, 2020: Oxford Biomedica signs Development, Manufacture & License Agreement with Beam Therapeutics for LentiVector Platform for next generation CAR-T therapeutics
Jun 01, 2020: Oxford Biomedica appoints Dr. Roch Doliveux as non-executive chairman
May 13, 2020: Oxford Biomedica receives MHRA approval for the first two manufacturing suites in Oxbox
May 06, 2020: Oxford Biomedica: Preliminary results for the year ended 31 December 2019
Mar 18, 2020: Oxford Biomedica : Business update
Dec 19, 2019: Oxford Biomedica extends commercial supply agreement by five years for manufacture of lentiviral vectors
Sep 04, 2019: Oxford Biomedica: Interim results for the six months ended 30 June 2019
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Oxford BioMedica Plc, Key Facts
Oxford BioMedica Plc, Key Employees
Oxford BioMedica Plc, Key Employee Biographies
Oxford BioMedica Plc, Major Products and Services
Oxford BioMedica Plc, History
Oxford BioMedica Plc, Other Locations
Oxford BioMedica Plc, Subsidiaries
Oxford BioMedica Plc, Key Competitors
Oxford BioMedica Plc, Ratios based on current share price
Oxford BioMedica Plc, Annual Ratios
Oxford BioMedica Plc, Annual Ratios (Cont...1)
Oxford BioMedica Plc, Annual Ratios (Cont...2)
Oxford BioMedica Plc, Interim Ratios
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Oxford BioMedica Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Oxford BioMedica Plc (OXB):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cairn Energy Plc (CNE):企業の財務・戦略的SWOT分析
    Cairn Energy Plc (CNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Xcel Energy Inc (XEL):企業の財務・戦略的SWOT分析
    Xcel Energy Inc (XEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Allinky Biopharma SL:医療機器:M&Aディール及び事業提携情報
    Summary Allinky Biopharma SL (Allinky) is a developer of small molecules for the treatment of cancer and inflammatory diseases. The company offers research and development of basic and clinical sciences and discovery of novel therapies. Its therapeutic agents comprise active site drugs, target prote …
  • National Bank Of Bahrain Bsc
    National Bank Of Bahrain Bsc - Strategy, SWOT and Corporate Finance Report Summary National Bank Of Bahrain Bsc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Zynex Inc (ZYXI):医療機器:M&Aディール及び事業提携情報
    Summary Zynex Inc (Zynex), formerly Zynex Medical Inc is a medical technology company that designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. The company’s products include NexWave, a dual channel, multi-modality interferential current, tra …
  • Kyivstar JSC:企業の戦略的SWOT分析
    Kyivstar JSC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Orion Diagnostica Oy-医療機器分野:企業M&A・提携分析
    Summary Orion Diagnostica Oy (Orion Diagnostica), a subsidiary of Orion Oyj, is a medical equipment company that develops, manufactures clinical diagnostic and hygiene monitoring tests. Its product portfolio provides diagnosis and treatment management kits, point of care systems, ready to use kits, …
  • Diamond Offshore Drilling Inc (DO)-石油・ガス分野:企業M&A・提携分析
    Summary Diamond Offshore Drilling, Inc. (Diamond Offshore) is an offshore oil and gas drilling company, which provides contract drilling services to the energy industry. It operates through a fleet of offshore drilling rigs comprising semisubmersibles, jack-ups, and dynamically positioned drillships …
  • Affymetrix, Inc.-医療機器分野:企業M&A・提携分析
    Summary Affymetrix, Inc. (Affymetrix) provides life science, and molecular diagnostic products for analysis of biological systems at gene, protein and cellular level. It offers products for two major applications, namely, genotyping and gene expression. Affymetrix offers three families of instrument …
  • DeRoyal Industries Inc:医療機器:M&Aディール及び事業提携情報
    Summary DeRoyal Industries Inc (DeRoyal) is a medical device company that develops, manufactures and markets healthcare products. The company’s products portfolio includes surgical instruments and accessories, acute care products, patient protection products, orthopedics, rehabilitation products and …
  • Dino Polska S.A (DNP):企業の財務・戦略的SWOT分析
    Dino Polska S.A (DNP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Garmin Ltd:企業の戦略・SWOT・財務情報
    Garmin Ltd - Strategy, SWOT and Corporate Finance Report Summary Garmin Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Octapharma AG:企業の戦略・SWOT・財務分析
    Octapharma AG - Strategy, SWOT and Corporate Finance Report Summary Octapharma AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Amphastar Pharmaceuticals Inc (AMPH):製薬・医療:M&Aディール及び事業提携情報
    Summary Amphastar Pharmaceuticals Inc (Amphastar) is a specialty pharmaceutical company that develops, manufactures and markets generic and proprietary injectable, intranasal and inhalation products. It also sells insulin active pharmaceutical ingredient (insulin API) products. The company’s product …
  • Triodos Bank NV:企業の戦略・SWOT・財務情報
    Triodos Bank NV - Strategy, SWOT and Corporate Finance Report Summary Triodos Bank NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Cafe De Coral Holdings Limited
    Cafe De Coral Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Cafe De Coral Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Global Tungsten & Powders Corp.:企業の戦略・SWOT・財務情報
    Global Tungsten & Powders Corp. - Strategy, SWOT and Corporate Finance Report Summary Global Tungsten & Powders Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Allianz Insurance plc:企業の戦略・SWOT・財務情報
    Allianz Insurance plc - Strategy, SWOT and Corporate Finance Report Summary Allianz Insurance plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Landsvirkjun hf:電力:M&Aディール及び事業提携情報
    Summary Landsvirkjun hf (Landsvirkjun) is a state-owned energy utility that conducts the generation and transmission of electricity in Iceland. It generates electricity through several renewable sources such as hydro, geothermal, and wind. Through subsidiaries, the company also offers telecommunicat …
  • ERG SpA (ERG):企業の財務・戦略的SWOT分析
    ERG SpA (ERG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆